COVID-19: "We may not be in a good position in the fall": Moderna CEO

COVID-19: “We may not be in a good position in the fall”: Moderna CEO

The majority of Moderna’s (MNRA) revenue comes from foreign governments – which are preparing for a continued need for COVID-19 vaccines this year.

As the United States waits for funding and the United States Food and Drug Administration (FDA) decides which virus strain to attack through recalls, Moderna and other vaccine companies predict that the decline in l Immunity will become a concern.

“This virus is not getting any less contagious,” Moderna CEO Stephane Bancel told Yahoo Finance. “As you see more and more infectious variants… We’re not done with mutating this virus,” he said.

The biggest risk in the fall, if the build-up is delayed, is the possibility of hospitals refilling with those who are most vulnerable, Bancel said.

The increased circulation from the intersection of decreasing immunity and a more transmissible variant, as seen with more subvariants of Omicron in the United States and abroad, is the real risk. , did he declare.

“We have a risk in the fall – if we don’t have the recall campaign early enough – that we may not be in a good position in the fall,” Bancel said.

Meanwhile, increased global circulation is also fueling the germination of more variants.

Of the $5.9 billion in vaccine revenue in the first quarter of this year – a significant jump from $1.7 billion in the first quarter of 2021 – a majority comes from countries other than the United States, according to Moderna. .

Meanwhile, the World Health Organization has pushed the company to share its vaccine recipe even if it doesn’t order more doses through the COVAX facilities program for low- and middle-income countries.

Moderna said at its annual shareholder meeting that it sells its vaccine starting at $7 per dose to these countries and that it has waived patent enforcement for the vaccine, in addition to its factory plans in the country. Kenya in the coming years.

During an earnings call on Wednesday, Chief Financial Officer David Meline said COVAX is another source of uncertainty for the company’s 2022 projections.

COVAX is “effectively the country demand consolidator” and must confirm country requests before confirming its order to Moderna, Meline said.

Follow Anjalee on Twitter @AnjKhem

Read the latest financial and business news from Yahoo Finance

Follow Yahoo Finance on Twitter, instagram, Youtube, Facebook, Flipboardand LinkedIn

Leave a Comment

Your email address will not be published.